Raymond James reaffirmed their outperform rating on shares of Immunovant (NASDAQ:IMVT – Free Report) in a research note published on Thursday, Marketbeat.com reports. The firm currently has a $36.00 price target on the stock. IMVT has been the subject of several other reports. UBS Group lowered their price target on Immunovant from $42.00 to $41.00 […]

HC Wainwright reaffirmed their buy rating on shares of Viking Therapeutics (NASDAQ:VKTX – Free Report) in a report released on Wednesday morning, Benzinga reports. HC Wainwright currently has a $90.00 price target on the biotechnology company’s stock. Several other equities research analysts also recently commented on VKTX. JPMorgan Chase & Co. initiated coverage on Viking […]

StockNews.com cut shares of Amphastar Pharmaceuticals (NASDAQ:AMPH – Free Report) from a buy rating to a hold rating in a research note issued to investors on Thursday. Several other equities research analysts have also commented on AMPH. Needham & Company LLC restated a hold rating on shares of Amphastar Pharmaceuticals in a research note on […]

Stephens reiterated their overweight rating on shares of 10x Genomics (NASDAQ:TXG – Free Report) in a report released on Thursday, Benzinga reports. Stephens currently has a $30.00 price objective on the stock. TXG has been the subject of several other reports. Leerink Partners initiated coverage on 10x Genomics in a research report on Tuesday, September […]

Fiera Capital Co. (TSE:FSZ – Get Free Report) has received an average rating of “N/A” from the zero analysts that are currently covering the company, MarketBeat.com reports. A number of equities research analysts have recently commented on FSZ shares. TD Securities reduced their target price on shares of Fiera Capital from C$8.00 to C$7.50 in […]

RODMAN&RENSHAW upgraded shares of Kyverna Therapeutics (NASDAQ:KYTX – Free Report) to a strong-buy rating in a research note published on Wednesday morning, Zacks.com reports. KYTX has been the topic of a number of other reports. JPMorgan Chase & Co. decreased their target price on shares of Kyverna Therapeutics from $39.00 to $33.00 and set an […]

HC Wainwright restated their buy rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) in a research report report published on Friday, Benzinga reports. HC Wainwright currently has a $60.00 price target on the biotechnology company’s stock. ARWR has been the topic of a number of other reports. Piper Sandler reissued an overweight rating […]

HC Wainwright reaffirmed their neutral rating on shares of Sage Therapeutics (NASDAQ:SAGE – Free Report) in a report released on Wednesday morning, Benzinga reports. HC Wainwright currently has a $25.00 price target on the biopharmaceutical company’s stock. Other equities research analysts also recently issued reports about the company. Scotiabank dropped their target price on Sage […]

Mr. Cooper Group (NASDAQ:COOP – Free Report) had its target price raised by Barclays from $103.00 to $108.00 in a research report released on Tuesday, Benzinga reports. They currently have an overweight rating on the stock. Several other research firms also recently issued reports on COOP. Piper Sandler boosted their price objective on Mr. Cooper […]

EF Hutton Acquisition Co. I upgraded shares of Biomea Fusion (NASDAQ:BMEA – Free Report) to a strong-buy rating in a research note issued to investors on Wednesday, Zacks.com reports. A number of other equities research analysts have also weighed in on BMEA. HC Wainwright raised their price objective on shares of Biomea Fusion from $15.00 […]

Cantor Fitzgerald reissued their overweight rating on shares of DoorDash (NASDAQ:DASH – Free Report) in a research report report published on Monday morning, Benzinga reports. The firm currently has a $160.00 price objective on the stock. A number of other equities analysts also recently issued reports on DASH. Benchmark reissued a buy rating and set […]

HC Wainwright reaffirmed their buy rating on shares of Viking Therapeutics (NASDAQ:VKTX – Free Report) in a research report report published on Wednesday morning, Benzinga reports. They currently have a $90.00 target price on the biotechnology company’s stock. A number of other brokerages also recently commented on VKTX. JPMorgan Chase & Co. initiated coverage on […]

B. Riley reissued their buy rating on shares of Novavax (NASDAQ:NVAX – Free Report) in a report published on Thursday, Benzinga reports. They currently have a $26.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $23.00. Several other equities analysts also recently commented on the company. JPMorgan Chase & […]

HC Wainwright restated their buy rating on shares of Regulus Therapeutics (NASDAQ:RGLS – Free Report) in a research report report published on Tuesday, Benzinga reports. HC Wainwright currently has a $10.00 price target on the biopharmaceutical company’s stock. Several other analysts also recently commented on RGLS. Canaccord Genuity Group raised their price objective on shares […]

UBS Group assumed coverage on shares of Kyverna Therapeutics (NASDAQ:KYTX – Free Report) in a research note published on Thursday, MarketBeat reports. The firm issued a buy rating and a $13.00 target price on the stock. KYTX has been the topic of several other reports. Rodman & Renshaw initiated coverage on Kyverna Therapeutics in a […]

Voyager Therapeutics (NASDAQ:VYGR – Get Free Report) was upgraded by research analysts at StockNews.com from a “hold” rating to a “buy” rating in a note issued to investors on Friday. Other equities analysts also recently issued research reports about the stock. Wedbush lowered their price target on shares of Voyager Therapeutics from $8.00 to $7.00 […]